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Abstract 
Evidence-based practice (EBP) is a well-established framework for supporting 
clinical decision-making in the discipline of speech-language pathology. The benefits of 
using evidence to inform clinical practice are acknowledged by clinicians and researchers 
alike. Even so, after over two decades of EBP advocacy, much clinical uncertainty remains 
and models supporting the evaluation of interventions require review and reconsideration. 
The EBP model, while promoting positive principles, can be argued to be conceptually 
flawed because it suffers from a lack of attention to and explicit valuing of other forms of 
knowledge crucial to the formation of realistic and judiciously informed decisions. We 
propose that the evaluation of interventions would be better supported by an explicit 
knowledge management approach reflecting a range of evidence and knowledge. One worked 
example is presented to demonstrate what using such an approach can produce in terms of 
intervention information. 
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Introduction 
Evidence Based Practice 
Evidence-based practice (EBP) has been a well-established framework for supporting 
clinical decision-making in the discipline of speech-language pathology (SLP) as well as 
other in health professions since the late 1990s. EBP, which originated as evidence based 
medicine (EBM) in the medical profession, had a number of drivers. These included concerns 
about a reliance on expert judgement with its inherent variability, as well as the use of 
ineffective therapies in healthcare.1 Government and healthcare insurance agencies started to 
increasingly demand factual evidence for medical treatments, so that they could have a more 
objective basis for procuring the most clinically and economically effective healthcare 
available. Such political and financial drivers pushed forward the EBM agenda  in order to 
assure greater consistency and continuity of best practice and effective healthcare treatments.2 
The EBM movement, emphasizing that clinical decision-making should focus more explicitly 
on high quality scientific evidence, rather than on clinical intuition, was closely followed 
across nursing and the allied health professions.3  Professional associations, including those 
in speech and language pathology, now almost universally actively promote the EBP agenda. 
It is also linked with regulatory requirements for individuals to undertake continuing 
education (CE) and for services to be accountable for clinical effectiveness. The impact of 
EBP has been significant across all healthcare disciplines, and it has been labelled the ‘most 
important contemporary initiative committed to reshaping biomedical reason and practice’4 
(p. 1059). 
What is evidence based practice exactly? 
The most widely accepted original definition of EBM is that first published by David 
Sackett and colleagues5 which identified three distinctive components or ‘pillars’ of EBM: 
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best quality research evidence, experienced clinical judgement and factors relating to the 
individual patient. Dollaghan6 perhaps provides the clearest definition of EBP: ‘The 
conscientious, explicit and judicious integration of 1) best available external evidence from 
systematic research, with 2) best available evidence internal to clinical practice, and 3) best 
available evidence concerning the preferences of a fully informed patient’ (p. 2). All three 
pillars were intended to be considered in balance and to be given equal weight – most often 
represented visually as three overlapping circles, or as the three points of a triangle; as seen in 
ASHA’s model.7 
 
The primacy of efficacy evidence 
Despite the good intentions of EBP, as McCabe8 has recently argued “we seem to be 
no closer to closing the gap between research evidence and practice” (p. 300). There are a 
number of possible explanations to account for this. They include conceptual issues with the 
EBP model itself9 and an unintended and predominant focus on efficacy evidence over and 
above the other two pillars, with a perceived primacy for the experimental research paradigm. 
Positivist research designs alone however, are insufficient to fully reflect the effectiveness, 
impact and patient experience of complex interventions for highly heterogeneous 
populations. Dollaghan6 contends that this ‘emphasis on scientific evidence has 
overshadowed the other two components’ (p. 2) while McCurtin10 argues that EBP places a 
hierarchical value on certain types of evidence (e.g., RCTs) resulting in the model suffering 
from a lack of attention to, and development of, practice and patient evidence. Knowledge 
and evidence generated by clinicians and patients is crucial to the formation of realistic and 
judiciously informed decisions. The inherent assumption in EBP that valid knowledge 
emanates primarily from efficacy evidence can be said to be incompatible with the realities of 
clinical practice. This may, in part, explain difficulties with evidence implementation, 
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impacting our potential to make reasonably informed decisions.  Further, while some areas of 
SLP practice such as phonological interventions now have a relatively strong empirical 
evidence-base11,12 compared with some other areas of speech and language pathology 
practice, there is a low likelihood that the discipline’s evidence base will ever be complete 
and that efficacy evidence will ever be sufficient to support treatment evaluations.1,13   
 
The complexities of intervening 
We contend that EBP insufficiently acknowledges the complexities of the treatment 
process and the multiplicity of factors that can impact treatment outcomes. These include 
dynamics such as the therapeutic alliance and the placebo effect.14, 15 Furthermore, as Plesk 
and Greenhalgh16 point out, clinical uncertainty and ambiguity are normal components of 
intervening. The context within which we provide intervention is also increasingly 
acknowledged as pivotal17.  This includes organisational and environmental contexts and 
drivers such as funding, access to services, and the training and supports provided to 
practitioners.18-20 Even with empirically supported treatments, Greenhalgh and Maskrey9 
maintain that statistically significant benefits may be marginal in clinical practice and the 
inflexible protocols attached to some interventions may not be patient-centred. Thus, even the 
best efficacy evidence may be inapplicable to, or inappropriate for an individual patient or 
context.  
Given all this, it is unlikely that EBP alone can ever be entirely effective in answering 
all clinical dilemmas. As Berg & Slaattelid21 assert, using a research-only lens to evaluate 
interventions is “a reductive conceptualisation of intervention” (p. 1). In essence, simplifying 
treatment to its efficacy base fails to reflect the complexities of the treatment process, 
limiting our understanding of what contributes to therapy outcomes. Thus, the process of 
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intervening is the sum of a number of complex interacting components, and treatment 
outcomes cannot be solely explained by, or attributed to, the treatment or technique applied.  
 
Promoting a broad-based epistemological approach to evaluating interventions 
We argue that the evaluation of interventions requires a broad-based epistemological 
approach, reflecting multiple forms of knowledge and expanding on the range and depth of 
information conventionally used in EBP. The strength, legitimacy and validity of treatment 
evaluations and decisions can be bolstered when an explicit knowledge gathering approach is 
employed. Further, not engaging with a range of evidence and knowledge can result in much 
valuable information being lost to the treatment evaluation and decision-making processes 
and may impact treatment outcomes.  
Knowledge or evidence synthesis endeavours to summarize all relevant studies on a 
specific question. It can contribute to the understanding of discrepancies in the various 
evidence, and through highlighting gaps in the research evidence, help to identify future 
research areas.22 Knowledge synthesis itself is not a new concept23 but it typically refers to 
the integration of various types of efficacy evidence. In healthcare, knowledge synthesis has 
principally focused on systematic reviews of interventions22 and not the totality of available 
knowledge regarding a treatment. We contend that interventions can be understood from, and 
evaluated against, a number of propositions, and that doing so is a total evidence and 
knowledge approach (TEKA). This includes but is not limited to a comprehensive description 
of the intervention in question, an understanding of the context in which the treatment will be 
employed, and the collective patient evidence.  Further, employing such knowledge can help 
us to modify treatment and implementation plans to account for such evidence. It may even 
have the potential to override supporting research evidence if, for example, issues of 
treatment adherence and acceptability are apparent.  
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We acknowledge the growing attention within the field to the role of implementation 
science, including knowledge translation strategies which seek to address the processes and 
outcomes of efforts to bridge the knowledge-practice gap. Implementation science includes 
the methods and strategies that might influence how EBP is adopted by clinicians and 
organisations, and requires consideration of implementation contexts.24-26 We propose in this 
paper that independently of implementation processes and translation strategies, the evidence 
and knowledge which underpin interventions and which should influence clinical decision-
making regarding implementation, themselves require a comprehensive examination as a 
crucial component of efforts to improve practice.  The discussion presented here has been 
constructed to explore what those evidence sources or factors should include, and to 
demonstrate how this may be implemented in a systematic way. 
 
 
The benefits of practice and patient evidence 
 
The value of using efficacy evidence where it is available is not in dispute. Healthcare 
has the potential to become outmoded if the most current, up-to-date evidence is not 
incorporated into decision-making.27 However, as Sackett et al.5 argue, without due 
consideration of practice and patient evidence, our clinical practice risks becoming oppressed 
by research (efficacy) evidence. Clinical experience for example, can provide unique 
information and insights and offer an improved understanding of interventions, patient 
responses to individual treatments, and insights into contextual issues and constraints. 
Findings from a range of studies in the profession demonstrate that practice evidence is 
indeed important in the discipline’s decision-making.28,29 Additionally, understanding patient 
groups’ observations about an intervention also has the potential to provide further insights 
into commonly used interventions, including issues around adherence, usability and appeal. 
This in turn can provide clinicians with information on ways to improve the treatment 
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experience and adherence. Our understanding of practice and patient evidence at both 
individual and group levels remains considerably underdeveloped. This is especially so for 
systematically and rigorously acquired collective practice and patient evidence.30 We ignore 
such evidence when appraising treatments to the detriment of reasonable and reasoned 
decision making and positive treatment outcomes. Retrieving and integrating such 
information makes common sense.  
 
Current examples of evidence based and knowledge synthesis approaches in SLP 
There has undoubtedly been progress made with regard to recognising the value and 
importance of practice and patient evidence, as well as improving accessibility to it. Such 
progress is evident in efforts to promote shared decision making31 and research in patient 
public involvement strategies.32 The work of the James Lind Alliance on aphasia is an 
example of this.33 The experience of individuals with communication impairments is also 
well described, in for example, developmental speech disorders,34,35 developmental language 
disorders,36 and stuttering,37 with clear illustrations of the lived experiences and impacts of 
such communication disorders. In SLP, there are known databases and tools available, which 
enable SLPs to access evidence on interventions, such as ASHA’s Evidence Maps38 and in 
the UK, the Communication Trust’s What Works39 database of interventions for childhood 
communication disorders. ASHA’s Evidence Maps provide resources to support evidence 
informed practice. These evidence maps present recent publications relevant to each domain 
(‘external scientific evidence’, ‘clinical expertise’ and ‘client perspectives’) across a 
comprehensive range of disorders as well as professional roles (assessment, screening, 
service delivery and direct treatment interventions). What Works is a synthesis of knowledge 
across a systematic review of evidence, surveys of clinicians, and investigations of the 
preferred outcomes of children and their parents.41 While such databases have limitations, 
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they are clear examples for SLPs of the benefits of employing a range of information based 
on the three pillars of EBP. Both the understanding generated in terms of areas of 
convergence and difference among the three sources of knowledge, and the dynamic nature 
of the databases, represent important examples of how we might begin to build more 
comprehensive epistemological frameworks to support clinical decision-making.  
 
Evidence and knowledge not explicitly recognised in EBP 
 
The explicit incorporation of knowledge not formally recognised in the EBP model is 
also advocated. Such information includes contextual evidence, which has been shown to be 
a factor in treatment decision-making both in speech-language pathology8 and other health 
disciplines such as nursing41 and which has been advocated by a number of authors.42,43 Even 
so, despite its impact, such information is not often explicitly stated when forming treatment 
decisions. Research in speech disorders has contributed to our understanding of service 
delivery and contextual evidence.44,45 Highlighting the benefits of a TEKA approach, these 
latter studies draw attention to mismatches between client expectations and experiences of 
intervention, and indeed, between the models and intensity of intervention suggested by 
empirical literature and actual service delivery experiences. Integrating this type of 
knowledge combined with other information on intervention implementation - for example, 
fidelity of intervention in a phonological treatment programme,46 is a critical reminder for 
researchers of the gap between researcher-designed interventions (where evaluated in a 
research context) and the practical demands of the clinical setting.  
Beutow and Kenealy47 have also argued for additional forms of evidence, including 
judicial evidence and ethics-based evidence; it is remarkable how little information is 
available regarding such issues in the literature with reference to specific interventions. These 
include, for example, impacts such as treatment burden - defined as the patient workload 
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resulting from an intervention and the impact on patient functioning and well-being.48 
Incorporating such factors in a synthesised evidence and knowledge approach is consistent 
with the valuing of person-centred healthcare and shared decision making.  Helping patients 
participate in their own healthcare decisions depends on high-quality information from a 
range of valid sources. If patients are not truly informed, as Elwyn49 notes, they will be 
unable to assess what is important to them and to generate truly informed preferences. 
Additionally, explicit consideration of alternative treatment options is also proposed in 
TEKA, as it is deemed to be integral to a comprehensive evaluation of an intervention.  Such 
deliberation facilitates patient choice, contemplation of other possible treatment avenues, and 
explicit treatment comparisons, in addition to helping match treatments to the individual 
patient’s needs. Further, it can serve to waylay concerns about habitual, traditional or cultural 
treatment selections in speech-language pathology.8, 29, 50  
Finally, irrespective of other treatment knowledge, we contend that a clinician could 
reasonably judge the validity, scientific nature or reasonableness of an intervention, by either 
retrieving, or formulating, a clear description of that treatment , as outlined by Creaghead for 
example.51 This includes properties such as the theoretical proposition supporting the 
intervention and measures used to evaluate efficacy. Such an exercise encourages the 
clinician to engage explicitly with treatment components and rationales and to demonstrate a 
clear understanding of the treatment in question. Despite the importance of this, therapy 
descriptions in the literature are often unclear and underdeveloped. Ludemann et al.52 for 
example, investigated the adequacy of intervention descriptions in the SLP literature and 
found that no interventions were completely described either in the primary publications or 
from information retrieved from secondary locations.  Such poor reporting of therapy 
descriptions has major implications for understanding, using, explaining, replicating and 
validating treatments. Further, such deficits in the literature do not encourage clinical SLPs to 
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spend time exploring the characteristics, merits and deficiencies of treatments. There are 
some examples of research contributing to our knowledge in this area. Interventions for 
phonological disorders in childhood for example, have been generally well-described in terms 
of treatment theory including mechanisms of action,3 and Wren et al.11 have mapped details of 
intervention components. Surveys of clinical practice and clinical decision-making such as 
that conducted as part of the Better Communication Research Programme (BCRP), 54 have 
provided clinician reports (practice evidence) on intervention approaches, models, theories, 
and targets of intervention, including for phonological difficulties.55 Such evidence should 
encourage SLPs to actively engage with understanding interventions. We propose that SLPs 
prioritise conducting a treatment description exercise as a first TEKA step, given its 
importance in generating an understanding of core intervention characteristics. Spending time 
on formulating a full description of a treatment including for example, explicating the 
treatment theory and identifying how (and if) outcomes are measured, will facilitate SLPs 
considerably in evaluating individual treatments.   
   
A total evidence and knowledge approach (TEKA) 
The TEKA framework advocates using a broad range of evidence and knowledge as 
outlined in Table 1, to support the evaluation of SLP treatments and provide evidence for 
clinical decisions. This includes that which is advocated in the three pillars of EBP – although 
with extended definitions of practice and patient evidence – but also refers to other 
knowledge forms not incorporated by EBP but delineated in Table 1 and discussed in the 
previous text. It is our contention that complete and realistic treatment evaluations require 
more than efficacy, patient and practice evidence. TEKA thus raises an important central 
question, that is, what do we define as evidence and knowledge when evaluating treatments? 
There are two constituents integral to answering this question: to outline the various forms 
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that evidence and knowledge can take to assist in this process, and; to encourage the appraisal 
of knowledge in terms of validity or applicability, so that knowledge is not incorporated into 
evaluations and decision making uncritically.  
The evaluation of interventions can be carried out in two main stages. The first part is an 
overall evaluation of a unique intervention based on TEKA domains (Table 1) without 
reference to individual patients. This stand-alone exercise can be updated on a predetermined 
basis to account for new information. Individual patient evidence can be integrated when 
required with this core information, to facilitate individualised decision-making. Thus, the 
TEKA model proposes the following steps:  
1. Identify the intervention to be evaluated. 
2. Gather evidence and information for each of the domains highlighted in Table 1. 
3. Appraise the evidence and information retrieved for each knowledge form or domain 
where appropriate, using for example, published tools for research evidence. Sample 
questions have been provided in Table 2 to facilitate critical appraisal of information 
retrieved for the treatment description exercise. Consensus formation within SLP 
groups may also be useful for critically evaluating information retrieved. 
4. Summarise the evidence for the intervention according to the domains highlighted in 
Table 1 and plot on a text document or graphic document such as a mind map.  
5. When making a decision with regard to an individual patient, apply relevant 
individual patient information alongside the TEKA information, to facilitate clinical 
and shared decision-making. 
Table 1 outlines the knowledge forms under discussion and the specific TEKA components 
for the intervention evaluation. 
[insert table 1 here]  
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Evidence and knowledge appraisal  
Whilst advocating for the inclusion of multiple forms of knowledge to produce 
integrated, reasoned, and reasonable decision-making, the authors fully acknowledge the 
potential demands of such an exercise, including the need to evaluate the reliability of the 
knowledge incorporated.  This proposition regarding knowledge gathering and management 
is not a call to be less scientific, but to be more rigorous by engaging with a multiplicity of 
knowledge and to evaluate the validity of all retrieved knowledge. This model explicitly 
places the clinician at the centre of decision making and treatment evaluation, rather than 
delegating it to external agencies (i.e., through assigning primacy to efficacy evidence). It 
invites SLPs to take responsibility by engaging critically, proactively, and reasonably in the 
evaluation and employment of therapies and techniques.  
This task appears relatively straightforward for efficacy evidence given the 
development of hierarchies of evidence and critical appraisal tools. Appraisal of research 
evidence often yields insights regarding research quality, stringency of protocols, the nature 
of target populations, highly restricted participant criteria (which may not reflect clinical 
populations), biases and potential vested interests. Even decision support tools such as 
clinical practice guidelines require critique. A recent review of international stroke guidelines 
for example, identified poor, old and sometimes inappropriate evidentiary bases for 
recommendations regarding the dysphagia intervention of thickened liquids.56 Thus, a 
critical, rather than accepting approach to all retrieved knowledge, is essential in order to 
facilitate improved decisions. In essence, critical thinking in speech-language pathology, as 
advocated by Finn,57 is at the heart of treatment evaluations. Critical thinking incorporates 
both skills and dispositions and, as such, reflects not just SLPs ability to engage critically, but 
also their desire to employ higher order thinking skills. As Wade et al.58 define it: “Critical 
thinking is the ability and willingness to assess claims and make objective judgments on the 
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basis of well-supported reasons and evidence rather than emotion and anecdote” (p 6-7). 
Thus, as Finn59 observes, clinicians require well-developed dispositions toward and 
competency in critical thinking, to ensure adoption and judicious use of evidence and 
knowledge. 
 
Collective practice and patient evidence 
Knowledge appraisal applies to all forms of retrieved knowledge including practice 
evidence, which incorporates individual and group clinical opinion and experience. While 
often informative, opinion-based knowledge has the potential to be prone to confirmation 
bias60 and cannot be assumed to be highly rigorous, being judgment-based and therefore 
naturally subject to variability. This is one reason for promoting a collective voice approach 
to gathering practice (and patient) evidence per Table 1. In this approach, the collective 
experiences of individuals (clinicians and patients) who have used a specific intervention are 
gathered through research, or reviewed by engaging systematically with the literature. 
Clinicians can retrieve this type of patient evidence for example, by implementing a system 
of recording individual patient experiences regarding an intervention and then combining this 
evidence to form the collective voice. In employing the collective voice approach, we build 
substance, promote, and validate practice and patient knowledge; by publishing it we ensure 
that it is available in the same arena as efficacy evidence and that it is conferred with similar 
attention and consideration. Further, in the context of multiple examples of disharmony 
between research and practice, including the use of poorly empirically supported 
interventions, culturally-based treatments, and eclectic approaches to treatment,1,8,50 explicitly 
retrieving the practice reasoning for such interventions should lead to an improved ability to 
validate (or not) clinical practice/practice evidence. 
 
TEKA  
15 
 
Treatment description questions 
As previously noted, an often-underused means of evaluating treatment integrity is 
through an intervention description exercise. The literature provides direction regarding 
fundamentals in describing interventions.51, 59-62 Asking targeted questions such as those 
outlined in Table 2 can yield important and insightful knowledge and highlight gaps in 
information and logic. Thus, while the act of knowledge retrieval (i.e., learning/reading about 
a new treatment) is important, any treatment evaluation exercise can be considered poorly 
and incompletely performed if the knowledge retrieved is not also appraised. Sample 
questions that can be addressed through this exercise are highlighted in Table 2 and an 
example of a treatment description has been provided in Appendix 1. 
[insert table 2 here]  
 
TEKA example  
This paper calls for reasonably informed treatment decision-making and proposes 
what such knowledge might constitute. One example is presented to demonstrate what using 
such an approach might produce in terms of intervention information. The example relates to 
the bolus modification intervention of thickened liquids/fluids (TL) for a hypothetical patient 
(Johnny G) with dysphagia and aspiration post-stroke. For this intervention, relevant 
evidence and knowledge across the TEKA domains was retrieved and this is summarised in 
Table 3. The retrieved information, including details of supporting references are provided in 
Appendix 1.  
[insert table 3 here]  
 
The TEKA exercise for this intervention resulted in a sizeable volume of information 
as demonstrated in Table 3 and Appendix 1. Such information when combined with the SLPs 
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knowledge of a patient, would enable the clinician to form a reasonable, patient-centred, 
knowledge-based plan for management of the case in question. The exercise has served to 
reveal treatment strengths and challenges, encouraged engagement with treatment theory 
while highlighting knowledge gaps and knowledge certainties. Despite the limited research 
evidence base for using TL, it is known that 78% of dysphagia therapists generally, and 97% 
of SLPs working with people with dysphagia post-stroke employ this treatment.63,64 This 
exercise emphasizes how using multiple forms of evidence and knowledge encourages SLPs 
to explicitly engage in and rationalise clinical decision making. Using TEKA could help to 
facilitate reasonable judgements irrespective of whether SLPs choose to employ the 
intervention in question or not. 
 
Applying TEKA 
The authors are not suggesting TEKA is a simple exercise, nor do we underestimate 
the effort involved in applying such a model. It is likely to be time intensive particularly in 
the initial stages of an intervention evaluation. However, EBP itself has not proved to be an 
easy or apposite answer, and better models to support decision-making are still required. We 
appreciate that time is a scarce commodity for practicing clinicians, that limited time impacts 
service delivery for SLPs65-67 and that there is an inherent cyclical problem (clinicians don’t 
have time for this, but time is one of the reasons their treatment may not be effective). A 
worthwhile treatment evaluation cannot be accomplished without effort but will produce 
long-term clinical guidance and impact including regarding service delivery and treatment 
outcomes. It is certainly important for our discipline that we engage deeply with our 
treatment tools, that we can rationalise our treatment choices and defend our decisions based 
on evidence and knowledge. This is true whether they are empirically supported or not, but 
especially so in cases where the efficacy evidence is lacking. In a profession wedded to 
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scientific principles, SLPs should be engaged in developing argumentation regarding the 
treatments and techniques they use in practice. The suggestions below are intended to 
facilitate engagement with TEKA or similar exercises while acknowledging the time 
constraints of clinicians. 
1. SLPs can utilize shortcuts to commence this exercise by accessing components 
already completed, such as systematic reviews in the literature, or through work 
already available on SLP websites such as ASHA Evidence Maps38 and What 
Works.39 This can be added to by noting and plugging the gaps in knowledge 
observed. 
2. Academics and researchers can conduct TEKA exercises with students SLPs either in 
specific modules or as a team research project. Student pairs/groups can carry out 
individual elements of TEKA such as collecting or synthesising the patient evidence 
or conducting a treatment description exercise. The products of these individual 
exercises can be combined to generate a full treatment evaluation or TEKA map. New 
student cohorts can incorporate updates and additions from year to year. 
Dissemination of information generated by students should be encouraged, so that 
TEKA treatment evaluations benefit the larger SLP discipline. Dissemination can 
occur in variety of ways including via institutional repositories, conference 
presentations and posters, publications and workshops. 
3. SLPs can prioritise one element of the TEKA exercise at a time for example, the 
treatment description exercise, thus building the knowledge base over time. 
Alternatively, groups of regional SLP teams can agree which treatment requires 
evaluation, with each team responsible for carrying out one part of the TEKA 
exercise. The whole group can then combine their efforts to formulate a 
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comprehensive treatment evaluation and build a TEKA map. As for the students in 
point 2, this can be shared via various arenas with other SLPs.  
4. Clinicians can incorporate key TEKA aspects by explicating their client specific and 
theoretical knowledge. In clinical practice, much of the thinking processes become 
implicit – this applies not just to the knowledge underlying clinical decisions but to 
the reasoning supporting decisions as well. Treatment evaluations would be well 
supported by explicating both treatment and patient knowledge and by mapping this 
knowledge onto TEKA headings.  
5. We recommend building TEKA into existing activities and tasks to which clinicians 
already devote time (e.g. supervision/mentoring meetings, team meetings, training/CE 
sessions), rather than creating a new forum within which it will be discussed. 
Additionally, clinicians who report on a training event or who review a journal article 
to feedback to colleagues, could incorporate the TEKA questions in their review of 
the training or article. For example, what was learned about the intervention’s 
mechanism of action; what was learned about clients’/research participant’s 
experiences of this intervention; what are the issues we need to consider in employing 
this intervention with our client/caseloads. Clinical teams could present worked case 
examples using the template provided here. This could generate valuable reflection on 
the processes and application of this more holistic evidence-based planning approach, 
and facilitate increased confidence for individuals to embed this more widely. 
6. Partnering between clinicians and researchers could be beneficial in the sharing and 
combining of knowledge to co-produce a TEKA map for an intervention. This would 
play to each group’s strengths. Clinicians could, for example, very usefully inform the 
research community about those aspects of interventions that are not being described 
or captured in published empirical research. These may include client experiences of 
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an intervention and contextual evidence. As noted previously, they could also 
formally collate this information when delivering services to build the collective 
voice. Researchers and educational institutions could share newest empirical 
information, search results or systematic review summaries. 
 
Conclusion 
SLP researchers and clinicians need to explicitly employ a more comprehensive 
approach to intervention evaluation, such as that outlined in this paper in the form of TEKA. 
This includes extended interpretations of two of the three core elements that are advanced in 
the EBP model of which practice and patient evidence, we argue, are defined inadequately. It 
also includes but is not limited to, a comprehensive description of the intervention in 
question, an understanding of the context in which the treatment will be employed, and 
judico-ethics evidence.  Employing such knowledge can help us to rationalise treatment 
selections and modify treatment and implementation plans to account for such evidence. EBP 
is a fairly one-dimensional way of evaluating interventions and a top-down construct, which 
overestimates the role of efficacy evidence in clinical decision making and intervening. It is 
incumbent upon the discipline to look beyond the traditional model of EBP. A broader range 
of retrieved knowledge, representing a more grounded clinical understanding of intervention, 
should be incorporated more overtly into our intervention evaluations and clinical decision-
making. 
Complexity in using an approach such as TEKA will depend on the area of practice 
and the specific intervention under examination. Even in some relatively well-developed 
arenas (for example developmental speech disorders), whilst available evidence across 
interventions can now inform many of the elements of the framework, it is challenging to find 
an example of an intervention for one area of need, with information across each of the 
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knowledge forms identified in Table 1. In applying TEKA, though, SLPs must also be careful 
to avoid what Strauss68 calls the knowledge translation imperative, that is, that all knowledge 
must be translated into action. Instead, we need to ensure that there is a mature and valid 
reflection on the knowledge retrieved, prior to treatment decisions being enacted at the 
individual and service levels. 
A TEKA approach may provide some answers which have not yet been delivered by 
EBP and help allay fears of a reductionist approach to practice.22 TEKA acknowledges that 
there are multiple forms of legitimate evidence and knowledge and promotes reasonably 
informed clinical and shared decisions which are grounded in the totality of evidence and 
knowledge. It allows for the recognition of and open response to contextual issues and has the 
potential to be more explicitly patient-centric. A true synthesis approach such as that outlined 
here, can help reduce what Farr and Cressey69 describe as the tensions that exist between 
patient-centred, relational care and the pressures of efficiency and rationalisation. Moreover, 
it fosters clinical ownership of and academic/clinical partnerships in treatment evaluations, 
rather than delegating it to external forces - specifically efficacy evidence - and encourages us 
to focus on integration rather than implementation. This approach responds to calls by 
Greenhalgh and Maskrey2 who advocate for “real” EBP, which is characterised by expert 
judgment rather than mechanical rule following and includes making the ethical care of the 
patient its top priority. As they argue, “practitioners, together with their patients, must be free 
to make appropriate care decisions that may not match what “best (average) evidence” seems 
to suggest” (p 3). In doing so, clinicians must also be able to demonstrate clearly that they 
have arrived at those decisions in a logical, informed way.  
Adopting an approach such as TEKA may contribute towards more effective practice 
and optimal outcomes for the clients of speech-language pathology services. This would 
require the combined inputs and best efforts of both researchers and clinicians. TEKA makes 
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logical sense and compels us to examine our decision-making. It can provide added 
legitimacy to clinical decisions in the presence or absence of research evidence for an 
intervention. In effect, it aligns clearly with Sackett’s3 call to be “conscientious, explicit and 
judicious” (p 71) in making decisions about the care of individual patients. 
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Learning outcomes: As a result of this activity, the reader will be able to (1) Identify the 
various forms of knowledge and evidence which underpin comprehensive intervention 
evaluations; (2) Understand the importance of retrieving multiple forms of knowledge and 
evidence when evaluating interventions and forming clinical decisions;(3) Understand how 
individual forms of knowledge can contribute both uniquely and in combination to a better 
and broader understanding of an intervention, and; (4) Recognize the importance of critical 
thinking and knowledge appraisal in undertaking treatment evaluations. 
 
CEU Questions & Answers  
1. Which of these forms of evidence is not in the original definition of evidence based 
practice (EBP)? 
a. Clinician experience 
b. Efficacy evidence 
c. Contextual evidence 
d. Patient values and experience 
e. All of the above 
2. Which non-efficacy evidence and knowledge might we consider when conducting 
intervention evaluations and forming clinical decisions? 
a. Judico-ethics evidence 
b. Contextual evidence 
c. Collective practice evidence 
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d. Collective patient evidence  
e. All of the above 
3. A clinician should be able to reasonably judge the validity or reasonableness of an   
intervention by: 
a. Checking if other SLPs are using it 
b. Accepting the therapy originators’ position 
c. Performing a treatment description exercise 
d. Asking a colleague’s opinion 
4. Collective patient or practice evidence refers to which of the following: 
a. Individual opinion 
b. Individual experience 
c. The experience and perceptions of a group of people familiar with the   
    intervention in question and retrieved from either conducting or synthesizing  
    the research 
d. The opinions and experiences of colleagues and friends 
5. SLPs are central to the judicious and comprehensive evaluation of the interventions 
they employ. To perform as such they must: 
a. Accept other clinician’s opinions 
b. Act as critical thinkers 
c. Follow authority figures 
d. Utilize efficacy evidence without reference to other forms of knowledge and 
evidence 
Answer Key 
1. c 
2. e 
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3. c 
4. c 
5. b 
 
Appendix 1: Information retrieved relevant to components of knowledge management, 
regarding use of thickened liquids (TL) for aspiration for people with dysphagia (PWD) 
post-stroke and for hypothetical patient Johnny G. 
 
Description of therapy  
The TL intervention is an established bolus modification treatment used to 
prevent/reduce aspiration in people with dysphagia. It comes in various forms including pre-
thickened drinks but is most typically given by adding a thickening agent (starch or gum 
based) in powder form to regular drinks. Drinks can be thickened to various consistencies 
(based on national/international descriptors) appropriate to the individual’s needs, as 
determined by a speech-language pathologist (SLP) after clinical/instrumental assessment. It 
is designed to slow bolus speed and thus increase swallow safety by minimising aspiration 
risk.70,71 Slowing bolus speed, theoretically means that the bolus is retained in the oral phase 
of the swallow for longer, that there is more time to organise/ initiate the swallow, and that 
the bolus should move through the pharyngeal phase more slowly. This implies that 
individuals with delayed or disorganised swallows resulting in penetration or aspiration 
would benefit most from this intervention.  It would also lead to the question as to whether 
individuals with oral stage disorders (e.g. problems moving the bolus anteriorally-
posteriorally) might find a thicker consistency more difficult. Candidacy tends to be decided 
on an individual basis; ideally this is done using instrumentation (i.e. videofluroscopy, VFSS, 
or fibreoptic endoscopic examination of swallowing, FEES). Newman et al.71 have called for 
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the development of highly specified candidacy criteria to “establish the optimal viscosity 
level for each phenotype of dysphagic patients” (p. 232).  
Individual outcomes are best evaluated via instrumentation, specifically VFSS or FEES, 
which can provide pre and post-intervention evidence for individual cases. Other measures 
include negative findings, specifically reduction in coughing on drinking, and lack of or 
reduction in occurrence of aspiration (difficult to gauge in silent aspirators) and of aspiration 
pneumonia. For this population, TL is known to have side effects or risks. These include 
effects on oral and pharyngeal transit times, increases in oral and pharyngeal residue, and 
increased risk of dehydration.70-73 It may also be that the oral effort may be increased as 
muscles may need to work harder to move the thicker liquid. Further, thickened liquids are 
known to be poor at quenching thirst. They also result in poor flavour release, and effects of 
delayed dissolution and disintegration of some medications have been demonstrated with 
TL.74 Starch-based thickeners have been shown to contain their consistency with human 
saliva less well than gum-based thickeners75. 
 
Research evidence 
Recent systematic reviews (SRs) for this intervention are available and referenced 
below and these represent the highest level of efficacy evidence.  Most evaluate the evidence 
for TL in people with dysphagia (PWD) for a range of conditions. Although the evidence 
base remains currently inadequate and often contradictory,71,73,76,77 the consensus from most 
recent systematic reviews is that there is some evidence for TL reducing the risk of airway 
invasion.71,73,78. Most of these reviews also conclude that the evidence in favour of TL is not 
strong. One meta-analysis77 concluded there was no significant difference in the risk of 
pneumonia in aspirating patients who took thin liquids with safety strategies, compared with 
those who took thickened liquids only. In an SR conducted specifically with regard to stroke,  
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Foley et al.79 concluded, consistent with most reviews, that TL is associated with a reduced 
risk of aspiration (in the acute stages of stroke) but strong research support is lacking. Most 
stroke clinical guidelines recommend TL either in isolation or as one element of a 
multicomponent treatment programme. These recommendations are often made using older, 
sometimes inappropriate, evidence and may be based on the consensus of the guideline 
development group.56 
 
Practice evidence 
78% of dysphagia therapists generally and 97% of SLPs working with PWD post-
stroke use TL.63,64 It is ranked in the top three dysphagia interventions, and 85% of SLPs 
regard it as effective.63,80. This high use in the profession in the absence of clear supporting 
evidence suggests a cultural influence on use, which should be considered. However, it is 
likely that clinicians retrieve individual patient evidence via clinical observations and 
instrumental techniques to support administration of TL and without which it would not 
continue to be used to such a high degree. A recent qualitative study of 22 SLPs working with 
PWD post-stroke regarding the TL intervention81 found that TL was employed by SLPs as a 
first step on the treatment ladder and use pivoted on safety-first reasoning. SLPs also 
perceived that there were limited treatment alternatives for reducing the risk of aspiration. 
Both clarity and contradictions around TL use were revealed, with SLPs acknowledging 
multiple factors which impact treatment effectiveness including hospital, patient and product 
issues.  
Own hypothetical clinical opinion, group consensus, known experts 
“I have NUMBER years clinical experience working in acute settings with patients 
with dysphagia including those PWD post-stroke. I have used TL frequently to treat 
aspiration risk, and this has been the main treatment used in the hospital for aspiration. I 
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find TL generally effective especially in cases where patients need time to initiate a swallow, 
where there is no anterior spillage, and especially in the acute stages, when other dysphagia 
interventions may not be possible. However, given the limited access to instrumentation in 
this hospital I cannot always provide case evidence of treatment effect. Also, I am aware that 
there are other variables at play which may impact outcomes including general recovery. In 
addition, I know that many of my patients with stroke are discharged before I can assess 
outcomes so there are cases where I am unable to follow up and cannot evaluate how they 
have done on the treatment. I have discussed this with my colleagues, and we are generally 
agreed that it is a useful treatment in the acute stages, but we also appreciate that patients 
don’t like it and there are treatment adherence issues. We have been trying other options 
recently including risk feeding. I have also been in contact with NAME, who is a national 
expert in the area, and she advises that individual patient clinical evidence, such as that 
retrieved from videofluroscopy or FEES, and the patient’s opinion will be the best way to 
evaluate the treatment’s effectiveness and usability.” 
 
Patient evidence 
The TL treatment has been associated with discontent among PWD resulting from a 
range of conditions.82,83. Non-adherence rates with TL are reported to vary between 40% and 
80%.82,84 In Logemann et al.’s85 large scale study, a sample of 711 PWD who trialled three 
aspiration interventions were shown to prefer non-TL-based treatments such as postural 
maneuvres and preferred to risk pneumonia than to use TL. Stroke-specific patient evidence 
is sparse. McCurtin et al.28 interviewed 14 community dwelling PWD post- stroke and found 
that participants disliked TL and this dislike impacted clinically in terms of adherence, 
hydration and quality of life. Lack of sensory appeal was important in framing patient dislike 
of the treatment. Participants’ involvement in and understanding of reasons for prescription 
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of TL was poor, leading to uncertainty regarding the treatment. The authors concluded that 
TL can be considered a burdensome treatment from multiple perspectives including product 
palatability, treatment uncertainty and treatment adherence issues. Two other studies86,87 
included stroke patients as a subset in their samples with similar results. In the Swan et al.87 
study, participants linked TL with a worse quality of life. This dissatisfaction is noted even 
among health professionals in the acute environment. Lim et al.’s88 healthcare utilities study 
for example, found that the health professions participants would prefer to sacrifice multiple 
years of their life instead of using TL.  
Patient’s opinion, values, preferences 
“I (the clinician) discussed the treatment with the patient/partner in question. Johnny 
G is in the acute stages post-stroke, has comprehension and expression difficulties and is not 
able to meaningfully participate in shared decision making at this stage. His wife explained 
that he isn’t a big drinker generally. I explained the treatment options including TL. She felt 
that Johnny G would be highly unlikely to drink a thickened drink and that she is concerned 
about him coughing and choking. She would like to “get him back to normal” and is happy to 
trial risk feeding as long as he is monitored closely. This decision will be reviewed tomorrow 
as his status improves.” 
 
Contextual evidence 
Costs 
There is evidence which highlights the cost to the health services if a patient with 
stroke gets pneumonia from aspiration while in the hospital. These include longer 
hospital stays, increased cost, greater disability and poor nutrition while in the hospital.89 
However, as O’Keefe90 argues, reduction in pneumonia resulting from TL remains unproven. 
There may also be additional costs involved which need to be considered including the costs 
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for treating dehydration and its consequences resulting from TL.90 For some patients, 
depending on the system, there is also a cost for the product itself. This varies from patient to 
patient, geography and length of time on the treatment. The monthly costs for American 
patients on TL is $174 - $289 while the annual cost to the NHS in England is circa £14 
million per year.90,91  
Implementation 
Murray et al.92 conducted a survey of health care professional prescribing and 
monitoring practices of TL. Respondents highlighted institutional factors such as attributing 
inadequate fluid intake to the hospital system (i.e., reporting that patients on TL are not 
offered enough thickened fluid or their consumption is not monitored closely enough). Some 
suggested that the patient’s functional disabilities (immobility, poor fine motor control, 
communication and/or cognitive impairment) resulted in them being unable to open packages 
and access drinks independently. Mixing of TL to specified individual consistencies is often 
problematic and there is evidence that staff, including aides, nurses and SLPs, do not reliably 
mix consistencies.80,93 Hospitalised individuals have also been found to have insufficient 
access to containers of liquids, difficulty opening drink containers, and difficulty accessing 
staff to assist them with drinking.74 Such findings raise concern about the impact of training 
of staff, the monitoring of preparation practices and treatment fidelity. Further, thickened 
drinks are sometimes not drunk quickly enough and thickener may dissolve and not be as 
effective.  
Use of TL for other purposes 
Because patients on TL typically receive drinks solely via this means, thickened 
drinks can be used for other purposes including to achieve hydration and ingest 
medications.74,81 This often means the treatment is being used for other purposes and may 
impact on fidelity and safety.  
TEKA  
37 
 
Local/national contextual information here such as policy, resource constraints.  
“It is standard practice in our hospital to use this treatment for all patients at risk of 
aspiration due to dysphagia. This practice is supported by the professional association’s 
guidelines regarding treating aspiration. We do not have regular access to instrumentation 
such as VFSS and FEES so are unable to assess each patient individually at time of treatment 
commencement. While we provide training to staff and have notices with directions on 
consistencies above patient beds, staff turnover and general busyness often mean that 
guidelines are not adhered to. Additionally, jugs of unthickened water are frequently left at 
bedsides of patients requiring TL. If patients are discharged home while still requiring the 
treatment, we find this is often done without a prescription for TL or the knowledge of the 
SLPs. As a department, in the last 6 months we have been incrementally trialling risk feeding 
and are developing protocols with the nursing teams on the acute wards. We plan to discuss 
this option with patients going forward.” 
 
Judico-ethics based evidence 
Thickeners are commercial products; thus, there are naturally vested interests in 
maintaining their use in healthcare. Empirical, clinical and patient rather than commercial 
interests should always be at the forefront of decision-making. Often informed consent for 
treatment is difficult to obtain in the acute stages of post-stroke, as capacity to give consent is 
reduced. Guidelines for obtaining informed consent including working with carers can be 
used for this purpose, with the issue revisited with the patient once capacity improves. Issues 
pertaining to patient impact need consideration, especially the principle of “do no harm”, as 
patient evidence suggests that this treatment is disliked by individuals and has impact on 
quality of life and well as the potential to create treatment burden.28,87 There is a need to 
weigh treatment benefit against treatment burden for each individual.  
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Legal evidence where known 
“I (the clinician) am not aware of any legal precedents regarding this treatment” 
 
Other treatment options 
SLPs perceive that there are limited treatment options for aspiration and that TL is the 
best available.81  
Free water protocols (FWPs): FWPs are a possible option. Murray et al.94 found that they are 
only used 14% of the time in healthcare facilities. FWPs provide access to unthickened water 
but require strict oral hygiene protocols.  
Chin tuck/down: This postural manoeuvre is well used in practice typically as part of an overall 
swallowing programme.63 The intent of postural techniques is to improve function and 
compensate for abnormalities that have not yet been rehabilitated.89 For these techniques, 
consistent with TL, there is limited evidence for their effectiveness and constraints such as the 
ability of the healthcare providers to ensure protocols and compliance. Fraser and Steele95 
concluded that the use of chin down during teaspoon administration of a bolus with PWD post-
stroke should be avoided unless verified by VFSS. In their retrospective review of charts and 
VFSS exams of patients with neurogenic dysphagia, Socanato et al.96 found that the chin tuck 
should benefit dysphagic patients with delayed swallowing and reduced laryngeal elevation, 
and that the effectiveness of the chin tuck is related to the overall degree of dysphagia. They 
concluded that the more severe the dysphagia, the less effective the manoeuvre and that it is 
potentially more useful in ‘mild dysphagia’ 
Risk-feeding/no treatment: Risk feeding essentially refers to feeding with acknowledged risk 
and implies an acceptance of the risks of oral feeding for that patient. Risk-feeding can take 
many forms varying with each individual case and the risks taken likewise vary based on 
each PWD. In some cases, the risks will be small or putative while in others they will be 
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great. According to Sommerville et al,97 the swallow is unlikely to improve on a risk-feeding 
regimen. With PWD post-stroke in the acute stages they are often not in a position to 
understand the risks. Potential benefits, risks and patient opinion need to be clearly stated. 
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Tables 
Table 1 TEKA components for the intervention evaluation 
 
Knowledge form Examples /definitions 
Intervention 
description  
Information which 
describes and  
explains the 
treatment in 
question 
 
Classification - Category of intervention into which the treatment fits. 
Definition - Statement which describes the treatment. 
Procedures - Steps demonstrating exactly how to carry out treatment. 
Theory - The proposal or hypothesis that describes the actual nature of the 
process that transforms the intervention into the desired outcome. 
Aims - The specific goals of treatment - skills / functions targeted and to what 
intent. 
Ingredients - What the clinician does/actions taken in order to effect change 
in the targeted areas. 
Mechanism of action - The specific mechanism by which an effect/change is 
produced. 
Candidacy criteria - Criteria (inclusion/exclusion) by which patients are 
considered appropriate for the treatment and why. 
Evaluation criteria - Outcome measures/tools and behaviours which provide 
basis for evaluating treatment success. 
Risk information - Knowledge regarding reported / known risks / side effects 
resulting from the treatment. 
Red flags - Whether the treatment raises concerns such as having 
pseudoscientific features (e.g., being authority based, immune to testing, 
having an implausible theory). 
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Alternative 
treatment options 
Knowledge about 
other treatments 
which target the 
same areas of need 
Other treatments - Identification / contemplation of other potential 
treatments which target the same problem, the comparison of these with the 
treatment under consideration and in the context of the individual in question 
and the context in which the treatment is to be provided. The “no treatment” 
option should also be considered, taking into account potential benefits, risks 
and patient preferences. 
Research evidence  
Results or 
outcomes of 
efficacy research 
Systematic reviews - Summaries including systematic reviews and meta-
analyses of the results of high-level, well-designed intervention studies.  
Randomised control trials – Experiments where bias is reduced as 
participants are allocated at random either to receive an intervention or to a 
control group 
Observational studies - Studies in which participants are observed in a 
systematic manner/certain outcomes are measured, with no attempt made to 
affect the outcome. 
Case series - A group or series of case studies involving patients who are 
given a similar treatment with no comparison group, but where participants 
may act as their own controls. 
Single case studies - Reports on single cases which involve forms of control 
i.e. treated / untreated items, repeated measures at baseline and the client 
acting as his/her own control.   
Clinical practice guidelines /evidence maps - Documents which summarise 
the evidence /make recommendations regarding specific interventions – where 
the recommendation is made based on research evidence. 
Practice evidence Individual clinical opinion - The experience / opinion of an individual 
clinician (e.g., the person providing the treatment in the immediate clinician-
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Knowledge 
accruing 
 from clinical 
experience 
patient dyad) or the opinion of other individual clinicians - for example, 
retrieved via blogs. 
Collective clinical voice - Peer-reviewed studies which include results (e.g., 
perceptions, experiences, attitudes) from a representative sample of healthcare 
providers who have experience of providing the treatment in question. 
Clinical consensus - The combined experience /consensus of a number of 
clinicians providing the treatment either locally, nationally or internationally 
based. 
Expert opinion - The experience/opinion of individuals or groups of people 
who are specialists / experts in the field / intervention. 
Clinical practice guidelines - Guidelines which make recommendations 
regarding specific interventions – where that recommendation is based on the 
consensus, usually of the guideline development group, who may or may not 
have experience of the specified intervention. 
Position statements - Statements by groups, usually professional 
organisations / working groups regarding that same intervention. 
Patient evidence 
Knowledge 
accruing 
 from patient 
experience 
Individual patient opinion (intervention recipient) - The opinion of the 
person using/potentially using the treatment regarding that treatment. 
Other patients’ experience of intervention – the opinion of singular patients 
who have previously been in receipt of the treatment. 
Carergiver opinion - The opinion of the carer (partner, spouse etc.) regarding 
the treatment. 
Patient values & preferences - The values/preferences of the person and (or 
their carers) (potentially) using the treatment. 
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Collective patient voice - Peer-reviewed studies which include results (e.g. 
perceptions, experiences, attitudes) from a representative sample of healthcare 
users, usually with the same presenting condition and who have experience of 
utilising the treatment in question. 
Individual clinical evidence - Evidence from clinical assessment / 
intervention with the individual in question, which is relevant to the treatment 
decision-making because of demonstrated response to the treatment. 
Patient groups - Experience of patient groups not directly involved in 
treatment delivery. Usually obtained via patient websites or advocacy groups. 
Contextual 
evidence 
Knowledge, 
typically practical 
in nature, accruing 
from and 
regarding factors 
which 
impact treatment 
implementation 
Cost - The direct cost of providing the treatment and the resources available 
from both the healthcare provider and healthcare user. 
Healthcare policy - Local / national/insurer policies related to the treatment / 
provision of services. 
Resources - Resources required to support treatment implementation, 
including but not limited to:  Access to equipment needed to implement the 
treatment; staffing requirements; the training required (e.g. type, intensity, 
length and cost) and the ability of the service to provide training; and the 
potential costs attached to equipment monitoring / maintenance / repair over a 
sustained period. 
Feasibility of protocol - The ability to provide / implement the treatment in 
its original form, which may impact treatment adherence/fidelity. 
Judico-ethics 
based evidence 
Information 
regarding legal 
The law of the land - The laws of the country / state where the treatment is 
being provided. 
Legal principles - Tenets guiding good practice, such as duty of care, breach 
of duty, reasonableness, do no harm. 
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issues and 
regarding the 
treatment which 
reflects on moral 
and ethical values 
Basic ethical principles - Principles such as informed consent for treatment 
and capacity to give consent. 
Impact issues- Issues pertaining to patient impact such as the influence of the 
treatment on quality of life, consideration of treatment benefit vs. treatment 
burden and expense impact (economic/time) on the patient. 
Commercial drivers - Drivers outside the immediate decision-making arena, 
such as whether the treatment is commercially driven / has vested interests, 
and how this might impact decision-making / available information. 
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Table 2 Sample questions for intervention description exercise 
Key questions Type of details required Explanatory notes  
How is the 
treatment 
generally 
described? 
What are the stated aims?  
Can you list the 
components? 
 
How should it be 
classified? 
 
What does the treatment aim to do and how? 
What are the activities involved to addresses the 
area of need, dosage including information about 
recommended frequency and intensity.  
How is the treatment categorised e.g., Intervention 
for grammar/ An AAC intervention. Sub-category:  
An explicit metalinguistic intervention/ A speech 
generating device.  
What is the  
protocol? 
Does the intervention 
provide specific 
directions on how to 
carry it out? 
 
 
 
Are the materials 
required clearly stated? 
Are directions to enable a clinician to carry out the 
treatment provided? 
Is the protocol comprehensive and replicable? 
Can a patient follow the directions? 
Is there a clear list of steps to introduce the 
intervention, feedback prompts to be used, what to 
do when the client achieves target or not?  
What are the materials to be used?  
Is there a cost attached to same? 
What are the 
theoretical 
propositions 
underpinning 
the treatment?   
What are the therapy 
principles and underlying 
theoretical proposition?  
Is the treatment theory 
scientific?  
 
What ate the bases upon which the therapy is 
developed and founded? 
What is the mechanism of action - the process by 
which the treatment effects change? 
Is theory and mechanism of action explicated and 
rational or unclear and unscientific? 
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Is treatment cause and 
effect misrepresented?   
Does it fit with current general and specific 
knowledge of underlying reasons for the area of 
difficulty and how learning mechanisms can be 
harnessed to promote change?   
Are suggestions that observed changes in patients 
are the result of the treatment open to question? 
Might changes observed be explained be due to 
other effects e.g. maturation, recovery, placebo? 
What types of 
evidence and 
knowledge are 
effectiveness 
claims based 
upon?  
 
 
 
 
 
Is the supporting 
evidence appropriately 
used and interpreted?  
 
 
 
 
 
 
 
What is the source of the 
evidence provided? 
 
 
 
 
Is evidence cited to support the treatment? 
What is the level and strength of the supporting 
evidence? E.g., systematic reviews of high quality 
trials versus limited case studies/care series. 
Are claims based on evidence of statistical and 
clinical significance including maintenance and 
generalisation of reported effects as appropriate?  
Are claims of effectiveness are based primarily or 
solely on case testimonials? 
Are negative findings /commentaries ignored? 
Do intervention effectiveness claims emanate from 
an authority figure?  
Is the evidence provided from a singular source or 
research team?  
Is the evidence cited published in peer reviewed 
journals? 
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Is the evidence and 
knowledge recent or 
dated?  
Is the treatment free from 
vested interests? 
Is the research testing the efficacy of the 
intervention up to date and harmonious with current 
theories and evidence? 
Does the opinion of an authoritative figure promote 
and sustain the treatment in the absence of evidence 
and solid theory? 
Are endorsements from celebrities or people with a 
commercial stake in the approach (e.g. 
manufacturer of dietary supplement, 
creator/designer of an app) used to recommend the 
treatment? 
Are conflicts of interest are explicitly stated or not?  
Who is the 
intervention 
targeting? 
 
Is the target population 
for the intervention 
clearly and logically 
described and derived?   
Is the population with whom the treatment has been 
targeted /researched clearly described? 
Are clear candidacy criteria provided or is the 
intervention applicable to a broad range of clinical 
populations who may often have diverse 
presentations /needs? 
Do candidacy criteria for the intervention make 
sense when considered alongside the treatment 
theory and mechanism of action? 
Do the participants in efficacy studies used to 
support the treatment match those for whom the 
intervention is promoted /designed? 
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Does the nature of the treatment fit with the 
developmental stage and/or nature of difficulty 
and/or aetiology/underlying deficits and/or client 
strengths and needs? 
What outcomes 
are used?  
Are outcomes provided 
and how can they be 
described?  
 
 
 
 
 
 
Can outcomes be 
attributed solely to the 
intervention in question? 
 
 
 
 
 
 
Are patient reported 
outcome measures 
(PROMs) used? 
Are outcomes measureable? 
Do outcomes measure what was targeted in the 
intervention? 
Are outcome measures provided? 
What types of outcomes are employed? 
Quantitative tools? Judgment based measures? 
Criterion referenced measures? 
Are the tools employed validated? Reliable? Have 
they good intra and inter-rater reliability? 
Have non-specific intervention variables such as the 
therapeutic alliance or a placebo effect been 
considered in evaluating outcomes? 
Can service delivery effects such as treatment 
intensity explain outcomes? 
Do measures account for /distinguish between 
proximal and distal outcomes e.g., proximal = a 
change in the area targeted such as swallow 
efficacy; distal = increased confidence swallowing. 
Are PROMs employed to measure patient report 
changes? Are PROMs the sole outcome measure 
employed? 
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Are treatment 
side effects and 
risks delineated? 
  
Are there side effects or 
risks to the treatment? 
 
 
 
 
 
Is treatment burden 
considered?  
 
 
 
 
 
 
 
 
 
 
 
What are the resource 
implications? 
 
Are side effects or risks highlighted in the treatment 
manual or reported by patients /clinicians in the 
literature or from experience? 
What are those side effects /risks and how are they 
obviated? 
Do side effects/risks supersede the possible 
treatment benefits? 
Can the treatment be comprehensively explained 
and easily interpretable to the patient/caregivers? 
Are there risks that it might be mis-adminstered? 
Is the patient workload too high generally or for 
particular patients? 
Does the patient have capacity to carry out the 
treatment? 
Have the treatment been evaluated in terms of 
benefits vs/ burdens? i.e. does the effect of the 
treatment (e.g. benefit from thickened liquids) 
outweigh/ or reduced pleasure in drinking, reduced 
liquid intake and possibility of dehydration? 
What are the varied resources implications for the 
service providers and the service users?  
Have cost, time, travel, number of sessions, 
required literacy skills, demands on family life and 
training required to support delivery of this 
intervention been considered? 
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Are the resource requirements rationalized in terms 
of the treatment benefits? 
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Table 3 Summary points of intervention evaluation exercise for illustrative example  
Knowledge 
form 
Summary points of thickened liquids (TL) evaluation 
Intervention 
description 
General: 
1. TL treats aspiration.  
2. Drinks can be prepared in various consistencies so the treatment can be 
individualised. 
3. TL products are gum or starch based. 
4. TL is purported to slow the bolus, which potentially enables improved swallow 
safety.  
5. Outcomes are typically demonstrated via instrumentation (especially for silent 
aspirators), a reduction in coughing on drinking and absence of/ reduction in 
occurrence of aspiration/aspiration pneumonia. 
6. Improvements may result from other factors in this population (e.g. spontaneous 
recovery). 
Side effects/risks: 
1. Effects on oral/pharyngeal transit times.  
2. Increases oral/pharyngeal residue.  
3. Increased risk of dehydration. 
4. Poor at quenching thirst. 
5. Poor flavour release.  
6. Effects of delayed dissolution of some medications. 
7. Starch-based thickeners retain consistency with human saliva less well. 
8. Oral effort may be increased. 
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Alternative 
treatment 
options 
1. Free water protocols have limited evidence but are also under-researched.  
2. Free water protocols require good oral hygiene to be maintained.  
3. Risk feeding is a possibility.  
4. Neither alternative is currently employed in the organisation.  
5. Risk protocols are currently being developed. 
6. Postural manoeuvres are an option. They have limited evidence and would need to 
be evaluated and monitored.  
7. In the early stages post-stroke, patients may not be able to carry out "complex" 
treatments.  
Research 
evidence 
1. Consensus from some recent systematic reviews is that there is some evidence for 
TL reducing the risk of airway invasion.  
2. Most reviews are not specific to the stroke population.  
3. Reviews conclude that the evidence in favour of TL is not strong.  
4. Most stroke clinical guidelines recommend TL either in isolation or as part of 
multi-component programme. 
5. Stroke clinical guideline recommendations for TL tend not be evidence based. 
Practice 
evidence 
General 
1. Most speech-language pathologists (SLPs) working with people with dysphagia 
post-stroke use the thickened liquids intervention.  
2. Intervention use is pivoted on safety-first reasoning. 
3. The intervention is used as a first step on the treatment ladder.  
4. SLPs believe thickening drinks is an effective intervention.  
5. SLPs perceive there to be limited treatment options for aspiration.  
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6. SLPs believe multiple local, individual, and contextual factors impact on treatment 
effectiveness. 
Local 
1. I (the clinician) have 10 years clinical experience working in acute settings with 
people with dysphagia including post-stroke.  
2. I have used thickened liquids frequently to treat aspiration risk.  
3. I find it generally effective, especially in cases where patients need time to initiate 
a swallow. 
4. My perceptions of effectiveness are based primarily on reduced clinical signs, and 
I repeat instrumental evaluations where available.  
5. Many stroke patients are discharged before I can follow them up.  
6. My colleagues agree it is a useful treatment in the acute stages. 
7. I have discussed this intervention with an expert who advises that individual 
patient clinical evidence and patient opinion is the best way to evaluate effectiveness 
and usabilty. 
Patient 
evidence 
General 
1. People with dysphagia across a range of conditions tend to dislike thickened 
liquids. 
2. Non-adherence rates vary between 40% and 80%. 
3. People with dysphagia prefer non- thickened liquids treatments.  
4. People with dysphagia post-stroke dislike this intervention, which may impact on 
adherence and hydration. 
5. Lack of sensory appeal is important in framing dislike of this intervention.  
6. Involvement in and understanding of reasons for thickening can be poor in people 
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with dysphagia post-stroke.  
7. People with dysphagia report TL impacts quality of life negatively. 
Individual clinical presentation 
1. Johnny G is two days post-stroke. 
2. He presents with a delayed swallow.  
3. He presents with a functional oral phase.  
4. Aspiration on videofluroscopy has been identified for unthickened liquids.  
5. Penetration is present for mildly thick liquids.  
6. There is no cough response to aspiration /penetration.  
7. No chest infections/pneumonia since admission. 
8. On nasogastric tube. 
9. Cognitive functioning is not of concern.  
10. Moderate language comprehension /expression problems are present. 
11. Mild dysarthria is present.  
12. Oral hygiene is poor. 
13. Johnny G is likely to be discharged next week if he improves. 
Individual preferences and opinion 
1. Johnny G's drinks of choice are tea and water  
2. His partner reports he is "not a big drinker anyway". 
3. Partner and patient not happy to proceed with thickening once treatment 
explained/demonstrated.   
4. Prefer options of risk feeding /free water protocols at this stage of recovery.  
Contextual 
evidence 
General 
1. Cost of product to hospital /patient. 
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2. In-patient pneumonia leads to longer hospital stays, increased cost, greater 
disability, and poor nutrition. 
3. Patients on thickened drinks are not offered enough thickened fluid and 
consumption is not monitored closely enough.  
4. All staff do not reliably mix consistencies as prescribed. 
5. Some patients have difficulty opening containers/packets or getting help to open 
them. 
 Local 
1. Thickened liquids is the treatment of choice within the hospital.  
2. Staff are trained on preparing thickened drinks, including new staff who undergo 
training as part of induction. 
3. Protocols for risk feeding and free water protocols are not fully developed.  
3. Use of individualised guidance posted as standard by beds irrespective of choice 
of treatment.  
4. Tendency within hospital to leave water jugs by all beds irrespective of whether 
patient on thickened drinks or not. 
Judico-
ethics 
evidence 
1.Thickeners are commercial products which may influence organisational use. 
2. Informed consent for thickened liquids is difficult to obtain in the acute stages as 
capacity to give consent is reduced. 
3. Carers can provide consent.  
4. Patient evidence suggests that thickened drinks are disliked by people with 
dysphagia thus increasing treatment burden and impact on quality of life.  
5. Need to weigh up treatment benefit versus treatment burden for Johnny G. 
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